• Directory of Taiwan

Viral Vector ManufacturingMarket 2022 Size, Revenue Analysis, Sales, Share and Research Depth Study 2030 | CAGR of 19.4% 

The global viral vector manufacturing market is expected to grow at a CAGR of 19.4% during the forecast period 2021-2027. The rising research base for innovative medicines has principally driven the industry for clinical applications, including clinical, preclinical, and regulatory studies.

Request To Download Sample of This Strategic Report :-

The COVID-19 pandemic has generated a lucrative opportunity for market participants, specifically in the vaccine production industry. The increasing significance of stem cell technology and the growing focus on cell and gene therapies will further propel the viral vector manufacturing market growth over the coming years.

Research in gene and cell therapy has gained prominence in the past few decades. Many such therapies use viral strands to deliver the specific gene that is expected to mitigate the genetic disorders. Gene therapy provides the potential to cure various diseases that include heart disease, diabetes, hemophilia, cancer, cystic fibrosis, and AIDS.

The number of gene treatments in the pipeline is over 360 in the U.S. alone, and more than 75% of these new therapies are still in an early stage of research & development. This will help the market growth for viral vector production.

COVID-19 pandemic is expected to positively influence the market’s growth for Viral vector manufacturing during the forecast period since these tracks are used in the R&D of COVID-19 vaccines. The adenoviral vector Ad5 is already being explored in the R&D of the COVID-19 vaccine, and this cost-effective approach has already been used for the production of the Ebola virus vaccine.

Growth Drivers
The global market for Viral vector manufacturing is driven by factors such as the increased R&D in cell and gene therapy in recent years, along with the adoption of these paths in developing vaccines and oncolytic therapies. The rapid use of stem cells in disease modeling and the emergence of the COVID-19 pandemic are expected further to propel the market growth for Viral vector manufacturing during the forecast period.

Request Full Report :-

Stem cell technology has seen rapid progress in recent years and induced pluripotent stem cell (iPSC) is the fastest growing stem cell segment with approximately 10% growth every year. The lentiviral segment is commonly utilized in the generation of iPSC.

Induced pluripotent cells (iPSC cells) are utilized in disease modeling and will help in the better understanding of the pathogenesis of various disorders such as congenital heart disease, premature aging, cancer, and other disorders. All these factors augment the upward growth of the global market for viral vector production.

Companies are involved in launching new viral platforms and are entering into collaborations, acquisitions, and funding in recent years. Thermo Fisher introduced Lentiviral Production System in May 2019, and this new system is cost-efficient and is expected to simplify researchers’ workflow. IForge Biologics raised USD 40 million Series A financing in July 2020.

Report Segmentation

By Vector
Adeno-Associated Virus (AAV)

By Workflow
Upstream Processing
Vector Amplification and Expansion
Vector Recovery/Harvesting
Downstream Processing
Fill Finish

By Application
Gene and Cell Therapy Development
Vaccine Development
Biopharmaceutical & Pharmaceutical Discovery
Biomedical Research

By End-use
Pharmaceutical & Biopharmaceutical Companies
Research Institutes

Request Full Report :-

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
  • South America
  • Brazil
  • Argentina
  • Rest of South America

Competitive Insight
Some of the major players operating in the market for Viral vector manufacturing include Addgene, Inc., Advanced BioScience Laboratories, Inc. (ABL, Inc.), Aldevron, L.L.C., Audentes Therapeutics, Batavia Biosciences B.V., BioMarin Pharmaceutical, BioNTech IMFS GmbH, Biovion oy, BlueBird Bio, Catalent Inc., Cell and Gene Therapy Catapult, CEVEC Pharmaceuticals GmbH, Cobra Biologics Ltd., Creative Biogene, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., General Electric Company (GE Healthcare), Genezen, Lonza, Merck KGaA, Miltenyi Biotec GmbH, Novasep Holding S.A.S, Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.), RegenxBio, Inc., SIRION Biotech GmbH, Takara Bio., Thermo Fisher Scientific, VGXI, Inc., Vibalogics GmbH, Vigene Biosciences, Inc., Virovek Incorporation, VIVEbiotech S.L., Waisman Biomanufacturing, Wuxi AppTec Co., Ltd., YPOSKESI.

What are the key findings of the report?

•This report provides comprehensive information on factors expected to influence the market growth and market share in the future.
•The report offers the current state of the market and future prospects for various geographical regions.
•This report provides both qualitative and quantitative information about the competitive landscape of the market.

Access full Report Description, TOC, Table of Figure, Chart, etc.-

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is a ‘one-stop solution’ for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:
Report Ocean:
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 – UNITED STATES Tel: +1 888 212 3539 (US – TOLL FREE)